Cure8 research brief
For people with IBD who do not respond to standard biologic doses, escalating the dose appears common in routine care and was associated with better short-term remission rates and reduced healthcare use in this registry analysis.
Adults with IBD (especially Crohn's), clinicians managing biologic therapy, and policymakers/funders involved in drug coverage decisions.
This study used a clinical quality registry (CCCare) to identify biologic treatment courses and defined DE as maintenance dosing above the standard average daily dose. About 37% of biologic courses underwent DE, typically within months of starting therapy, and most patients remained on DE at 12 months.
Improvements after DE included larger proportions meeting fecal calprotectin <250 µg/g, better PRO2 scores, and modest increases in endoscopic remission. The authors also report fewer subsequent endoscopies, radiology exams, and hospital admissions.
The paper highlights that lack of formal funding for DE in Australasia may delay or limit access to effective higher dosing, potentially increasing morbidity and costs.
This is a registry-based observational study from Australasia (CCCare) using real-world data and an abstract-level source. Associations reported do not prove causation; details on which specific biologics were escalated and individual patient factors require reading the full paper.
Review the original publication for the complete reporting, methods, and context.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
This trial directly tests common clinical strategies for managing loss of response to ustekinumab in Crohn’s disease. The findings may change whether doctors routinely escalate to 4-weekly dosing after an IV reinduction,...
This study looks at upadacitinib in people with Crohn’s disease who did not respond to anti-TNF drugs — a common and challenging clinical situation.
Patients considering switching biologics or clinicians choosing a second‑line therapy may care because the study suggests ustekinumab had better long‑term persistence and improving remission rates compared with anti‑TNF...
